Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 151 publications
Cumulative high-risk surgical and pathologic features predict recurrence after resection of early-stage node-negative non-small cell lung cancer.
Journal: JTCVS open
Published: February 10, 2026
Segmentectomy for Occult N1 NSCLC: THE DATA CHALLENGE the Traditional Dogma.
Journal: The Annals of thoracic surgery
Published: October 27, 2025
Segmentectomy for Occult N1 NSCLC: A Consideration for a Nuanced Approach and Future Investigations.
Segmentectomy for Occult N1 NSCLC: A Consideration for a Nuanced Approach and Future Investigations.
Journal: The Annals of thoracic surgery
Published: October 20, 2025
Optimal Margin for Sublobar Resection of Invasive Lung Adenocarcinoma Presenting as Mixed Ground-Glass Nodules.
Journal: The Annals of thoracic surgery
Published: August 30, 2025
Factors Associated With Provider Decision-Making of Early-Stage Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy or Sublobar Resection.
Journal: Clinical lung cancer
Published: August 21, 2025
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
Journal: The New England journal of medicine
Published: June 02, 2025
Real-time margin assessment for video-assisted thoracic surgery: A pilot clinical trial.
Journal: JTCVS techniques
Published: May 25, 2025
Delayed Esophagectomy After Chemoradiation Is Not Associated With Increased Mortality or Recurrence.
Delayed Esophagectomy After Chemoradiation Is Not Associated With Increased Mortality or Recurrence.
Journal: Journal of surgical oncology
Published: May 18, 2025
Long-term survival for preoperative versus postoperative treatment of N2 lung cancer: The importance of complete adjuvant therapy for occult N2 disease.
Journal: JTCVS open
Published: February 10, 2025
Lung cancer recurrence after neoadjuvant immunotherapy.
Journal: The Journal of thoracic and cardiovascular surgery
Published: February 10, 2025
Provider Bias in Decision Making About Treatment of Early-stage Lung Cancer With Stereotactic Body Radiation Therapy or Sub-lobar Resection.
Journal: Clinical lung cancer
Published: January 27, 2025
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 08, 2025
Last Updated: 09/26/2026